Compare CLST & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CLST | RFL |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 61.1M |
| IPO Year | 2021 | 2017 |
| Metric | CLST | RFL |
|---|---|---|
| Price | $16.42 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 103.5K |
| Earning Date | 04-30-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.16 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $10.67 | $1.12 |
| 52 Week High | $16.98 | $3.19 |
| Indicator | CLST | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 52.39 |
| Support Level | $15.20 | $1.35 |
| Resistance Level | $16.98 | $1.38 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 29.41 | 32.73 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.